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Abstract
Background: Tobacco consumption is a preventable risk factor for chronic disease and complicates the treatment
of medical conditions. Therefore, the German health insurance company AOK NORDWEST has developed a
collaborative smoking cessation intervention for individuals with cardiovascular disease, chronic obstructive
pulmonary disease and heavy smokers, with the aim of reducing tobacco consumption. The objective of the
study ENTER is to evaluate the effectiveness of the collaborative smoking cessation intervention and determine
its cost-effectiveness.
Methods/Design: This study is a cluster-randomized controlled trial conducted with 40 medical practices that are
being selected from different geographic regions in Germany. Participating medical practices will be randomly
allocated to either the intervention or control group. Within the medical practices, a total of 800 patients will be
recruited for participation in the study and blinded to group assignment. Patients are included in the study if they
are 18 years or older, insured by AOK, heavy smokers (smoke at least 20 cigarettes per day) and/or suffer from
chronic obstructive pulmonary disease or cardiovascular disease. Exclusion criteria are patients who are nonsmokers,
who have cognitive impairments or who are illiterate. Physicians from medical practices in the intervention group
will motivate patients to participate in a smoking cessation program offered by the health insurance, refer them to
the program and ask about their program participation. Physicians from medical practices in the control group will
provide usual care. Data collection will take place on the date of study inclusion and after 6 and 12 months. The
primary outcome is the amount of cigarettes consumed during the past 30 days, 12 months after the initial medical
consultation. Secondary outcomes are abstinence from smoking, health-related quality of life and respiratory
complaints. Moreover, a process evaluation and health economic analysis will be performed.
Discussion: The results of this study will help to determine whether the collaborative smoking cessation intervention
is an effective and feasible way to promote smoking cessation in the primary care setting and provide evidence
regarding its cost-effectiveness.
Trial registration: German Clinical Trials Register DRKS00006079. Registered 4 June 2014.
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Background
In Germany, around 29 % of the adult population cur-
rently smoke, and 25 % of these smokers consume 20
cigarettes or more per day [1]. The negative health effects
associated with regular tobacco consumption are well
known: tobacco consumption is a risk factor for cancer,
cardiovascular and respiratory diseases [2]. Furthermore,
tobacco consumption complicates the treatment of many
chronic diseases. Therefore, key elements in the treatment
and secondary prevention of chronic obstructive pulmon-
ary disease (COPD) [3] and coronary diseases are to avoid
exposure to tobacco smoke [4]. Within the first year, ab-
stinence from tobacco leads to an improvement in the
lung function of COPD patients as measured by Forced
Expiratory Volume in 1 second (FEV1). The progressive
decrease in FEV1 can be stopped in the further course of
treatment [5]. As a form of secondary prevention, smok-
ing cessation reduces the risk of mortality associated with
smoking-related diseases [6]. Moreover, a 50 % reduction
in cardiovascular events is expected as a result of tobacco
cessation [7]. Consequently, a number of different strat-
egies to prevent tobacco consumption have been incorpo-
rated into prevention guidelines [8].
There are a number of different smoking cessation
methods such as self-help measures, pharmacological
aids, alternative treatments and individual or group
counseling [9]. In contrast to pharmacological aids, cer-
tified smoking cessation programs are reimbursed in
Germany. The smoking cessation program “Rauchfrei
Programm” developed by the Institute for Therapy Re-
search (IFT) in Munich and the German Federal Center
for Health Education (Bundeszentrale für gesundheitliche
Aufklärung) is most frequently offered by German health
insurance companies [10]. The program consists of 3 to 7
weekly meetings with up to 12 participants and individual,
telephone-based counseling [3]. The program is based on
a cognitive-behavioral approach with the aim of creating
problem awareness, motivating and achieving attitude as
well as behavior change. Data from an evaluation (single
group, pre-post-follow-up design) of the smoking cessa-
tion program in a routine setting with 1,319 participants
demonstrate that the program is effective [11]. On aver-
age, participants smoked 20 cigarettes per day at the be-
ginning of the program (SD = 9) and were heavily
nicotine-dependent [11]. The abstinence rate was 61 %,
and 32 % after 1 year [11].
Despite the availability of smoking cessation programs,
few smokers participate in the programs that are
currently offered. Only 1 % of the prevention programs
covered by public health insurances (e.g. physical exer-
cise, stress management and nutrition) are in the field of
substance abuse which mainly consists of smoking cessa-
tion programs (96 %) [12]. The low uptake of smoking
cessation programs indicates that there is a need for
innovative and networked strategies that motivate
smokers and individuals who suffer from smoking-
related diseases, such as cardiovascular disease and
COPD, to quit smoking [13]. For example, besides
extending and improving smoking cessation programs,
there is a need to disseminate more information about
available programs and to facilitate access to them [14].
This form of health promotion is based on the New
Public Health approach, which proposes that interven-
tions should be implemented on a behavioral as well as
a structural level [15]. According to this approach,
health behavior change does not only depend on the
individual person but also on the social, economic and
political environment.
General practitioners (GPs) play an important part in
facilitating access to smoking cessation programs be-
cause they are consulted by 70 % of smokers at least
once per year [16]. As pulmonologists and internists sit-
uated in individual offices are also frequently consulted
by smokers, they are considered equally important. For
the purpose of clarity, GPs, pulmonologists and inter-
nists are referred to only as physicians in the following.
Due to the frequent patient contact, the physician’s
office can be used to support and motivate smokers to
participate in smoking cessation programs. German
smoking cessation guidelines recommend that physicians
ask every patient about their smoking behavior and
provide smoking cessation advice [17]. This approach is
warranted because a number of studies have shown that
smoking cessation advice offered by physicians increases
quit rates [7].
Therefore, the health insurance company AOK NORD-
WEST (referred to as AOK in the following) has devel-
oped a Collaborative Smoking Cessation Intervention
(CSCI), which builds on these findings and is directed at
individuals with cardiovascular disease or COPD and
heavy smokers. The CSCI concept is derived from an earl-
ier project by AOK aimed at reducing risk factors associ-
ated with a lack of physical exercise, which has been
successfully implemented in Westphalia-Lippe [18]. The
aim of CSCI is to decrease the rate of tobacco consump-
tion among individuals with cardiovascular disease, COPD
and heavy smokers, in order to improve quality of life and
overall therapeutic success.
Study aim and hypotheses
The aim of the present study is to evaluate the effective-
ness and cost-effectiveness of CSCI with respect to to-
bacco consumption, health status and health care costs,
compared to usual care. The main hypotheses are listed.
The primary hypothesis is as follows:
Patients in the intervention group smoke fewer ciga-
rettes per day (30-day prevalence) compared to patients
in the control group.
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The secondary hypotheses are as follows:
1. Patients in the intervention group are abstinent
from smoking more often compared to patients in
the control group.
2. Patients in the intervention group have higher
health-related quality of life compared to patients in
the control group.
3. Patients in the intervention group have fewer
respiratory complaints, compared to patients in the
control group.
The hypotheses related to the process evaluation are
as follows:
1. The amount of patients referred to the smoking
cessation program is greater in the intervention
group compared to the control group.
2. The amount of patients who attend the smoking
cessation program is greater in the intervention
group compared to the control group.
3. Cost-effectiveness (cost per reduced quantity-
frequency index) and cost-utility (cost per quality-
adjusted life year; QALY) are greater in the intervention
group compared to the control group.
Methods/Design
Study design
A two-arm, cluster-randomized controlled trial will be
conducted with approximately 40 medical practices, se-
lected from different regions in Germany (Westphalia-
Lippe and Schleswig-Holstein). Patients from these med-
ical practices will be assessed on the date of study inclu-
sion (t0) and after 6 (t1) and 12 months (t2). Cluster-
randomization is used with medical practices chosen as
the unit of allocation because it is most practical in this
setting and minimizes the risk of spillover effects from
the intervention to the control group [7]. Moreover, the
collaboration between physicians, their medical assis-
tants and AOK will be assessed via qualitative interviews
conducted 12 months after study begin. Finally, the in-
tervention’s cost-effectiveness will be assessed.
Recruitment and randomization
Recruitment of physicians
Letters of invitation to participate in the study will be
sent to physicians situated in individual medical prac-
tices by AOK. Letters will be followed up via telephone
by a research assistant from the University Medical
Center Hamburg-Eppendorf, in case of no response.
Physicians who agree to participate in the study via writ-
ten consent will be randomly assigned to the intervention
or control group (the intended allocation ratio is 1:1).
Randomization
Physicians participating in the study will be stratified by
geographic region and randomly allocated to either the
intervention or control group by means of permuted
block-randomization with randomly varying block sizes
(blocks of two and four). The trial statistician will gener-
ate a random number sequence via computer on the
basis of which one envelope will be created for each
medical practice with the result of the allocation. When
a medical practice is included in the study, a research
assistant without prior knowledge of the sequence will
open the next envelope (one at a time) and allocate the
medical practice to the intervention or control group.
Recruitment of patients
Within participating medical practices, patients will be
recruited for participation in the study and blinded to
group assignment. In order to participate in the study,
patients must be 18 years or older, insured by AOK,
heavy smokers (smoke at least 20 cigarettes per day)
and/or suffer from COPD or cardiovascular disease.
Exclusion criteria are nonsmokers and patients who have
cognitive impairments or are illiterate.
Measures and evaluation
Measures
Patients are handed a questionnaire (t0) at the medical
practice containing the quantity-frequency index [19],
the Fagerström Test for Nicotine Dependence (FTND)
[20], SmoCess-GP [21], Questionnaire to assess readiness
to change among smokers (FÄR) [22], the Short Form SF-
12 [23], the EQ-5D-3L [24] and the Visual Simplified
Respiratory Questionnaire (VSRQ) [25]. Physicians specify
the patient’s smoking status and the diagnosis for the
severity of the cardiovascular disease or COPD on a docu-
mentation sheet. Follow-up takes place after 6 (t1) and 12
(t2) months via telephone by a research assistant from the
University Medical Center Hamburg-Eppendorf. More-
over, qualitative interviews will be conducted with physi-
cians assigned to the intervention group, their medical
assistants and the AOK smoking cessation program
instructors after 12 months in order to determine the
network’s quality. The measures used in this study are val-
idated and have been used previously in similar studies.
All measures are listed in Table 1 along with the time of
measurement and person being assessed.
Evaluation
Outcome evaluation
Primary and secondary outcomes are assessed on the
individual participant level 12 months after the initial
consultation with the physician. The primary outcome is
the amount of cigarettes smoked per day (30-day preva-
lence), measured via the quantity-frequency index [19].
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Secondary outcomes are the rate of abstinence from
smoking, quality of life measured via sum scores calcu-
lated from the SF-12 [23], and respiratory complaints
measured via sum scores calculated from the Visual
Simplified Respiratory Questionnaire [25].
Process evaluation
The process evaluation is performed at the cluster-level
and based on semi-structured telephone interviews that
will be conducted with physicians assigned to the
intervention group, their medical assistants and AOK
course instructors 12 months after inclusion into the
study. During the interviews, a focus will be placed on
perceived barriers and facilitators to the implementation
of the intervention. Further questions will concern experi-
ences with implementing the intervention under routine
conditions, the collaboration with AOK, organizational
matters and perceived advantages of the intervention. In
addition, physicians will be asked about their experiences
with motivating patients and AOK course instructors will
Table 1 Measurement process and time
Time of measurement Person Constructs
Screening Patient Smoking status (>20 cigarettes per day yes/no) and/or presence of cardiovascular disease or COPD
Questionnaire (t0) Patient Smoking status:
Fagerström Test for Nicotine Dependence (FTND) [20]
Quantity-frequency index (30 days): Amount of days on which patients smoked during the last 30 days,
average amount of cigarettes consumed per day [19]
SmoCess-Questionnaire to assess primary care for smoking cessation [21]
Health status:
Health-related quality of life SF-12 [23]
EQ-5D-3L [24]
Respiratory complaints: Visual Simplified Respiratory Questionnaire (VSRQ) [25]
Motivation:
Questionnaire to assess readiness to change among smokers (FÄR) [22]
Documentation sheet (t0) Physician Smoking history (number of years of smoking), relevant clinical indications (severity of cardiovascular
disease or COPD)
Questionnaire (t1) Patient Smoking status:
Fagerström Test for Nicotine Dependence (FTND) [20]
Quantity-frequency index (30 days): Amount of days on which patients smoked during the last 30 days,
average amount of cigarettes consumed per day [19]
SmoCess-Questionnaire to assess primary care for smoking cessation [21]
Health status:
Health-related quality of life SF-12 [23]
EQ-5D-3L [24]
Respiratory complaints: Visual Simplified Respiratory Questionnaire (VSRQ) [25]
Motivation:
Questionnaire to assess readiness to change among smokers (FÄR) [22]
Questionnaire (t2) Patient Smoking status:
Fagerström Test for Nicotine Dependence (FTND) [20]
Quantity-frequency index (30 days): Amount of days on which patients smoked during the last 30 days,
average amount of cigarettes consumed per day [19]
SmoCess-Questionnaire to assess primary care for smoking cessation [21]
Health status:
Health-related quality of life SF-12 [23]
EQ-5D-3L [24]
Respiratory complaints: Visual Simplified Respiratory Questionnaire (VSRQ) [25]
Motivation:
Questionnaire to assess readiness to change among smokers (FÄR) [22]
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be asked about the participation of patients during the
courses. The amount of patients participating in smoking
cessation courses will also be assessed. Moreover, the
health economic analysis will serve to determine the inter-
vention’s cost-effectiveness (cost per reduced quantity-
frequency index) and cost-utility (cost per quality-adjusted
life year; QALY) from the perspective of the German
statutory health insurance. The analyses will be performed
with AOK routine data covering the period 12 months be-
fore until 12 months after the intervention. Routine data
will contain information about the use of health care ser-
vices and related costs due to hospital care, outpatient
medical and psychotherapeutic care by physicians and
specialists, medication, medical aids, medical rehabilita-
tion, inability to work and sickness allowance. The costs
of the intervention will be calculated per patient following
a micro-costing. This will include the compensation
physicians receive per recommendation as well as costs
resulting from the provision of the intervention, i.e. remu-
neration of course instructors, course materials and room
rent.
Study procedure
Medical assistants will screen patients for inclusion in
the study by means of a checklist. Patients who meet the
inclusion criteria will be informed about the study via a
study information. Patients who wish to participate in
the study will be asked to provide their contact details
on a separate form and complete the first questionnaire
(t0) during the waiting time, along with the informed
consent form and a contact information sheet. Patients
will be asked to return the questionnaire to a medical as-
sistant in a sealed envelope together with the informed
consent form and contact information sheet before leaving
the medical practice. Informed consent will be obtained
from all patients participating in the study. Medical assis-
tants will keep a list of all patients who were informed
about the study and a separate list of patients who partici-
pate in the study. Physicians will specify patient’s smoking
status and the severity of cardiovascular disease/COPD on
a documentation sheet. At the end of the survey phase,
the lists and documentation sheets will be sent to the
study center at the University Medical Center Hamburg-
Eppendorf. A 6-month (t1) and 12-month (t2) follow-up
will be carried out via telephone by a research assistant
using the information provided by patients on the contact
information sheet. Moreover, the collaboration between
physicians, their medical assistants and AOK staff will be
assessed via qualitative interviews conducted 12 months
after the start of the study by a research assistant. Tele-
phone interviews will be recorded digitally, transcribed
and analyzed via qualitative content analysis [26]. An
evaluation of the intervention’s cost effectiveness will also
be performed.
Collaborative smoking cessation intervention (CSCI)
Physicians in the CSCI group will receive a brochure con-
taining detailed information about the intervention, the
steps involved in delivering it to patients and the required
materials. The steps involved in delivering the intervention
are as follows: During a personal consultation physicians
motivate patients to participate in the smoking cessation
program. Patients who wish to participate in the program
are handed a flyer containing detailed information about
the date, time and place of the program and are instructed
to contact the nearest AOK branch office to register for the
program. Patients who fail to do so within 14 days are sent
a written reminder by AOK. Physicians issue a referral form
for each patient willing to participate in the program and
send it to AOK. Physicians receive a one-time payment of
€25.50 from AOK for every patient referred to the smoking
cessation program via referral form. During subsequent
consultations, physicians ask patients about their participa-
tion in the program. Physicians assigned to the control
group will provide usual care (defined as the care provided
by physicians under routine conditions, when not trained
to deliver the CSCI).
Statistical methods
Data analysis
The main research questions will be evaluated via mixed
models, which make it possible to examine effects and
their interactions on different levels (physicians and
patients). According to the intent-to-treat principle, all
randomized patients will be included in the primary ana-
lyses. In the analysis of abstinence rates, patients lost to
follow-up will be assumed to have returned to smoking
[27, 28]. Table 2 provides a summary of the hypotheses
along with comparison groups, statistical method and
the outcomes of interest. Other than the 6-month
follow-up conducted with patients via telephone, no in-
terim analyses are planned.
The telephone interviews conducted with physicians
and AOK staff will be recorded digitally, transcribed and
analyzed via qualitative content analysis [26]. The health
economic analysis will be performed by calculating
the incremental cost-effectiveness ratio (ICER) for the
12-month follow-up, based on routine cost data pro-
vided by AOK. As measures of effects, the quantity
frequency index, as well as QALYs, will be employed.
For this purpose, differences in the mean costs (C )
and mean effects (Ē) between intervention and con-





The nonparametric bootstrap procedure will be used to
perform the ICER’s uncertainty analysis. This procedure
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takes into account the skewness of cost data and the co-
variance of costs and QALYs. In order to control for
possible confounding variables and to account for
clustering, an alternative procedure (Net-Benefit Re-
gression) will be used. Cost-effectiveness acceptability
curves will be created in order to illustrate the statistical
uncertainty.
Sample size calculation
According to a survey of 11,000 physicians, on average,
53 patients are treated in medical practices per day [29].
Approximately 15 of these patients are health insured by
AOK, which holds one third of the nationwide market
share. According to epidemiological data, approximately
7 % of patients smoke 20 or more cigarettes per day. As-
suming a participation rate of 50 %, physicians should be
able to recruit around 10 patients for participation in
the study per month. A meta-analysis by Stead and
colleagues [7] demonstrates that among at-risk patients,
the relative risk of being abstinent from smoking at
follow-up is 1.65 for participants of intensive interven-
tions, compared to participants of minimal interventions
(with around 12 and 7 % cessation rates in the interven-
tion and control groups, respectively). This value was
transformed into a standardized mean difference
(Cohen’s d) due to the metric scaling of our primary
outcome. The expected small to moderate effect of
Cohen’s d = 0.30 requires that data from 352 persons are
available for sufficiently powered (β = 0.20) independent
samples t-tests (α = 0.05). Accounting for the effect of
clustering (intraclass correlation coefficient of 0.05)
[30, 31]suggests that data from 34 medical practices with
an average cluster size of 20 should be analyzed (340
patients per group, 680 in total). An estimated 15 %
drop-out rate for medical practices means that 40 med-
ical practices should be recruited. Due to an estimated
15 % of patients lost to follow-up, a total of 800 patients
will be recruited for participation in the study. Assuming
a 20 % participation rate in the smoking cessation
program, 68 patients from the intervention group are
expected to participate in the smoking cessation pro-
gram. Figure 1 illustrates the expected flow of medical
practices and patients through the study.
Ethical considerations
This research will be conducted in accordance with
the Declaration of Helsinki and ICH Good Clinical
Practice guidelines. The study has been designed in
consultation with the AOK data protection officer and has
been approved by the ethics committees of the medical
associations in Hamburg (Reg.-No. PV4628), Westphalia-
Lippe (Reg.-No. 2014-326-b-S) and Schleswig-Holstein
(Reg.-No. IV/EK189/14). The program “Programm
Rauchfrei” is well established and side effects are not
known, so that adverse events or ethical concerns are
not expected.
A participant information statement serves to inform all
patients about the study’s aim, procedure and data man-
agement. Moreover, patients will be given an informed
consent form and asked to complete it. Patients will also
be asked to provide their contact details (name and tele-
phone number) on a contact information sheet, so that a
research assistant from the University Medical Center
Hamburg-Eppendorf can contact them for the purpose of
conducting follow-up interviews. Until follow-up inter-
views have been completed, pseudonyms will be used and
the participant’s contact details will be stored separately
from questionnaire or interview data and the documenta-
tion sheet. Access to the final dataset will only be granted
to authorized staff at the University Medical Center
Hamburg-Eppendorf. Collaborating institutions will be
required to agree to data management procedures so that
access is restricted contractually. Participation in the study
is voluntary and can be withdrawn at any time by patients
without facing consequences or having to give an explan-
ation. In case patients withdraw from the study, their data
will be deleted.
Table 2 Hypotheses
Hypotheses Comparison Statistical method Outcome measure
Primary hypothesis
Smoke reduction CG-IG Mixed models Quantity-frequency index
Secondary hypotheses
Rate of abstinence CG-IG Chi-square Abstinence
Health-related quality of life CG-IG Mixed models SF-12
Respiratory complaints CG-IG Mixed models Visual Simplified Respiratory Questionnaire
Process evaluation hypotheses
Referral CG-IG Descriptive Amount of patients referred to the smoking cessation program via referral form
Uptake CG-IG Descriptive Amount of patients attending the smoking cessation program
Cost-effectiveness and cost-utility CG-IG ICER Quantity-frequency index, QALY
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Discussion
Purpose and use of the results
Funding innovative approaches in the field of prevention
depends on their demonstrated effectiveness according
to current guidelines [17]. The aim of this study is to
evaluate the effectiveness of CSCI [32]. CSCI builds on
previous research, which has shown that smoking cessa-
tion advice offered by physicians increases quit rates [33]
and that appropriate training leads physicians to ask pa-
tients about their smoking status [34]. The focus of CSCI
is laid on establishing local networks between AOK
and physicians. Therefore, the study results will help to
determine whether this is a suitable approach to support
smoking cessation in the primary care setting.
Moreover, the results will provide information regarding
the feasibility of implementing CSCI under routine condi-
tions. This information is valuable because CSCI is based
on current guidelines, which recommend that physicians
ask every patient about their smoking status [17]. The
results of this study are of further policy relevance because
they can inform the design of future behavioral and struc-
tural level interventions in the field of health services. Fur-
thermore, the findings of the economic evaluation will
provide insight concerning whether the intervention
proves cost-effective and whether medical cost savings
can be achieved in the short-term.
Generalizability of the study results may be limited
because physicians and patients willing to participate in
a study on smoking cessation could be more interested
and more engaged in smoking cessation activities com-
pared to the general population. In addition, tobacco
consumption will be measured via questionnaire, and
consequently, patients may over- or underreport the
amount of tobacco consumed. However, measuring
tobacco consumption via self-report measures is gener-
ally accurate and is most appropriate because the study
design does not allow for biochemical validation [35]. A
possible source of bias is that patients will be recruited
Fig. 1 Flow chart illustrating the expected flow of medical practices and patients through the study
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after medical practices have been randomly allocated to
the intervention or control group. In this case, the
allocation schedule is known, which may lead to biased
participant recruitment within medical practices [36].
Barriers to study completion
Possible barriers to the study’s implementation are seen
primarily in the willingness of physicians to participate
in research. However, this barrier will be addressed by
actively following up on invitation letters with no re-
sponse via telephone, engaging medical assistants in
study processes and assuring adequate reimbursement in
addition to training physicians individually. Despite these
precautions drop-out is expected, specifically for medical
practices that are assigned to the control group. However,
the expected drop-out has been taken into account during
sample size calculation. Another concern regarding the
study’s implementation is seen in the low response rate of
surveys. This concern will be addressed by conducting
follow-up surveys via telephone because these have previ-
ously resulted in response rates of up to 85 % in studies to
evaluate the program “Rauchfrei” by IFT [11].
Trial status
Participant recruitment started in June 2014 and is
expected to be completed in September 2015. This is the
first version of the study protocol and no amendments
have been made to the study design.
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